INNOGEN-B (02591) released its performance for the year 2025, with a net loss of 341 million yuan, an increase of 95.4% year-on-year.
Yinuo Pharmaceuticals-B (02591) announced its annual performance ending on December 31, 2025. The Group generated revenue of approximately RMB 131.5 million, mainly from the sales of Esipladantide in China. The net loss was RMB 341 million, an increase of 95.4% year-on-year; basic loss per share was RMB 0.79.
INNOGEN-B(02591) released its annual performance report for the year ending December 31, 2025. The group generated revenue of approximately 131.5 million yuan, mainly from the sales of Eysupargluc peptide in China. Net loss was 341 million yuan, an increase of 95.4% compared to the previous year; basic loss per share was 0.79 yuan.
Related Articles
US Stock Market Move | Energy storage concept stocks collectively rose, GE Vernova (GEV.US) rose more than 6%.
Storage chips are facing an exacerbation of supply-demand imbalance. Wedbush predicts that prices of some products will rise by more than 100%.
TIMELESS (08028) subsidiary plans to offer 40,000 tokens for subscription, expecting to raise over 22.57 million Hong Kong dollars to develop the precious metals business.
US Stock Market Move | Energy storage concept stocks collectively rose, GE Vernova (GEV.US) rose more than 6%.
Storage chips are facing an exacerbation of supply-demand imbalance. Wedbush predicts that prices of some products will rise by more than 100%.
TIMELESS (08028) subsidiary plans to offer 40,000 tokens for subscription, expecting to raise over 22.57 million Hong Kong dollars to develop the precious metals business.
